Extracellular matrix regulation of drug resistance in small-cell lung cancer

International Journal of Radiation Biology

Volumn 83, Issue 11-12, 2007, Pages 733-741

  Hodkinson, P S ^a   Mackinnon, A C ^a   Sethi, T ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Chemotherapy and SCLC; Extracellular matrix

Indexed keywords

BETA1 INTEGRIN; CASPASE 3; CYCLIN A; CYCLIN B; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; DNA FRAGMENT; DOXORUBICIN; ETOPOSIDE; FIBRONECTIN; GLYCOGEN SYNTHASE KINASE 3BETA; INTEGRIN ALPHAVBETA1; MITOXANTRONE; PHOSPHATIDYLINOSITOL 3 KINASE; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 3; VITRONECTIN RECEPTOR;

APOPTOSIS; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL PROTECTION; DOWN REGULATION; EXTRACELLULAR MATRIX; HUMAN; IMMUNOHISTOCHEMISTRY; IONIZING RADIATION; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; REVIEW; UPREGULATION;

CARCINOMA, SMALL CELL; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR MATRIX; HUMANS; INTEGRINS; LUNG NEOPLASMS; MODELS, BIOLOGICAL; PROGNOSIS; SIGNAL TRANSDUCTION;

EID: 36849038378     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.1080/09553000701570204     Document Type: Review

References (61)

1. Aoudjit F, Vuori K. 2001. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene 20:4995-5004.
2. Bepler G, Jaques G, Neumann K, Aumuller G, Gropp C, Havemann K. 1987. Establishment, growth properties, and morphological characteristics of permanent human small cell lung cancer cell lines. Journal of Cancer Research and Clinical Oncology 113:31-40.
3. Bonomi P. 2002. Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Seminars in Oncology 29:78-86.
4. Boonstra J. 2003. Progression through the G1-phase of the ongoing cell cycle. Journal of Cellular Biochemistry 90:244-252.
5. Boudreau N, Sympson Cj, Werb Z, Bissell MJ. 1995. Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science 267:891-893.
6. Brakebusch C, Fassler R. 2005. Beta 1 integrin function in vivo: Adhesion, migration and more. Cancer Metastasis Reviews 24:403-411.
7. Bramhall SR, Hallissey MT, Whiting J, Scholefield J, Tierney G, Stuart RC, Hawkins RE, Mcculloch P, Maughan T, Brown PD, Baillet M, Fielding JW. 2002. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. British Journal of Cancer 86:1864-1870.
8. Brognard J, Clark AS, Ni Y, Dennis PA. 2001. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Research 61:3986-3997.
9. Cappellini A, Tabellini G, Zweyer M, Bortul R, Tazzari PL, Billi AM, Fala F, Cocco L, Martelli AM. 2003. The phosphoinositide 3-kinase/Akt pathway regulates cell cycle progression of HL60 human leukaemia cells through cytoplasmic relocalization of the cyclin-dependent kinase inhibitor p27(Kip1) and control of cyclin D1 expression. Leukemia 17:2157-2167.
10. Diehl JA, Cheng M, Roussel MF, Sherr CJ. 1998. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes and Development 12:3499-3511.
11. Dou QP, Lui VW. 1995. Failure to dephosphorylate retinoblastoma protein in drug resistant cells. Cancer Research 55:5222-5225.
12. Falcioni R, Cimino L, Gentileschi MP, D'Agnano I, Zupi G, Kennel SJ, Sacchi A. 1994. Expression of beta 1, beta 3, beta 4, and beta 5 integrins by human lung carcinoma cells of different histotypes. Experimental Cell Research 210:113-122.
13. Fridman R, Giaccone G, Kanemoto T, Martin GR, Gazdar AF, Mulshine JL. 1990. Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. Proceedings of the National Acadamy of Science USA 87:6698-6702.
14. Gregorc V, Ludovini V, Pistola L, Darwish S, Floriani I, Bellezza G, Sidoni A, Cavaliere A, Scheibel M, De Angelis V, Bucciarelli E, Tonato M. 2003. Relevance of p53, bcl-2 and Rb expression on resistance to cisplatin-based chemotherapy in advanced nonsmall cell lung cancer. Lung Cancer 39:41-48.
15. Hannun YA. 1997. Apoptosis and the dilemma of cancer chemotherapy. Blood 89:1845-1853.
16. Hannun YA, Obeid LM. 1997. Mechanisms of ceramide-mediated apoptosis. Advances in Medical and Experimental Biology 407:145-149.
17. Hazlehurst LA, Damiano JS, Buyuksal I, Pledger WJ, Dalton WS. 2000. Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 19:4319-4327.
18. Hazlehurst LA, Valkov N, Wisner L, Storey JA, Boulware D, Sullivan DM, Dalton WS. 2001. Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells. Blood 98:1897-1903.
19. Hirasawa M, Shijubo N, Uede T, Abe S. 1994. Integrin expression and ability to adhere to extracellular matrix proteins and endothelial cells in human lung cancer lines. British Journal of Cancer 70:466-473.
20. Hodkinson PS, Elliott T, Wong WS, Rintoul RC, Mackinnon AC, Haslett C, Sethi T. 2006. ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through beta1 integrin-dependent activation of PI3-kinase. Cell Death and Differentiation 13:1776-1788.
21. Hovelmann S, Beckers TL, Schmidt M. 2004. Molecular alterations in apoptotic pathways after PKB/Akt-mediated chemoresistance in NCI H460 cells. British Journal of Cancer 90:2370-2377.
22. Hoyt DG, Rusnak JM, Mannix RJ, Modzelewski RA, Johnson CS, Lazo JS. 1996. Integrin activation suppresses etoposide-induced DNA strand breakage in cultured murine tumor-derived endothelial cells. Cancer Research 56:4146-4149.
23. Hui R, Finney GL, Carroll JS, Lee CS, Musgrove EA, Sutherland RL. 2002. Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells. Cancer Research 62:6916-6923.
24. Hynes RO. 1992. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69:11-25.
25. Katori H, Baba Y, Imagawa Y, Nishimura G, Kagesato Y, Takagi E, Ishii A, Yanoma S, Maekawa R, Yoshioka T, Nagashima Y, Kato Y, Tsukuda M. 2002. Reduction of in vivo tumor growth by MMI-166, a selective matrix metalloproteinase inhibitor, through inhibition of tumor angiogenesis in squamous cell carcinoma cell lines of head and neck. Cancer Letters 178:151-159.
26. Kouniavsky G, Khaikin M, Zvibel I, Zippel D, Brill S, Halpern Z, Papa M. 2002. Stromal extracellular matrix reduces chemotherapy-induced apoptosis in colon cancer cell lines. Clinical Experimental Metastasis 19:55-60.
27. Lauffenburger DA. 1996. Cell motility. Making connections count. Nature 383:390-391.
28. Lauffenburger DA, Horwitz AF. 1996. Cell migration: a physically integrated molecular process. Cell 84:359-369.
29. Lein M, Jung K, Ortel B, Stephan C, Rothaug W, Juchem R, Johannsen M, Deger S, Schnorr D, Loening S, Krell HW. 2002. The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model. Oncogene 21:2089-2096.
30. Liu BQ, Peto R, Chen ZM, Boreham J, Wu YP, Li JY, Campbell TC, Chen JS. 1998. Emerging tobacco hazards in China: 1. Retrospective proportional mortality study of one million deaths. British Medical Journal 317:1411-1422.
31. Lozonschi L, Sunamura M, Kobari M, Egawa S, Ding L, Matsuno S. 1999. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. Cancer Research 59:1252-1258.
32. Luscinskas FW, Lawler J. 1994. Integrins as dynamic regulators of vascular function. FASEB Journal 8:929-938.
33. Macaulay VM, O'Byrne KJ, Saunders MP, Braybrooke JP, Long L, Gleeson F, Mason CS, Harris AL, Brown P, Talbot DC. 1999. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clinical Cancer Research 5:513-520.
34. Massague J. 2004. G1 cell-cycle control and cancer. Nature 432:298-306.
35. Mazumder S, Dupree EL, Almasan A. 2004. A dual role of cyclin E in cell proliferation and apoptosis may provide a target for cancer therapy. Current Cancer Drug Targets 4:65-75.
36. Mettouchi A, Meneguzzi G. 2006. Distinct roles of beta 1 integrins during angiogenesis. European Journal of Cell Biology 85:243-247.
37. Michael M, Babic B, Khokha R, Tsao M, Ho J, Pintilie M, Leco K, Chamberlain D, Shepherd FA. 1999. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. Journal of Clinical Oncology 17:1802-1808.
38. Mitsiades CS, Mitsiades N, Koutsilieris M. 2004. The Akt pathway: Molecular targets for anti-cancer drug development. Current Cancer Drug Targets 4:235-256.
39. Naglich JG, Jure-Kunkel M, Gupta E, Fargnoli J, Henderson AJ, Lewin AC, Talbott R, Baxter A, Bird J, Savopoulos R, Wills R, Kramer RA, Trail PA. 2001. Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291. Cancer Research 61:8480-8485.
40. Osterlind K, Hansen HH, Hansen M, Dombernowsky P, Andersen PK. 1986. Long-term disease-free survival in small-cell carcinoma of the lung: A study of clinical determinants. Journal of Clinical Oncology 4:1307-1313.
41. Page K, Li J, Wang Y, Kartha S, Pestell RG, Hershenson MB. 2000. Regulation of cyclin D(1) expression and DNA synthesis by phosphatidylinositol 3-kinase in airway smooth muscle cells. American Journal of Respiratory Cell and Molecular Biology 23:436-443.
42. Phillips-Mason PJ, Raben DM, Baldassare JJ. 2000. Phosphatidylinositol 3-kinase activity regulates alpha -thrombin-stimulated G1 progression by its effect on cyclin D1 expression and cyclin-dependent kinase 4 activity. Journal of Biological Chemistry 275:18046-18053.
43. Resnitzky D. 1997. Ectopic expression of cyclin D1 but not cyclin E induces anchorage-independent cell cycle progression. Molecular Cell Biology 17:5640-5647.
44. Rintoul RC, Buttery RC, Mackinnon AC, Wong WS, Mosher D, Haslett C, Sethi T. 2002. Cross-linking CD98 promotes integrin-like signaling and anchorage-independent growth. Molecular Biology of the Cell 13:2841-2852.
45. Rintoul RC, Sethi T. 2001. The role of extracellular matrix in small-cell lung cancer. Lancet Oncology 2:437-442.
46. Schmidt M, Hovelmann S, Beckers TL. 2002. A novel form of constitutively active farnesylated Akt1 prevents mammary epithelial cells from anoikis and suppresses chemotherapy-induced apoptosis. British Journal of Cancer 87:924-932.
47. Sethi T, Rintoul RC, Moore SM, Mackinnon AC, Salter D, Choo C, Chilvers ER, Dransfield I, Donnelly SC, Strieter R, Haslett C. 1999. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo. Nature Medicine 5:662-668.
48. Sethi T, Rozengurt E. 1991. Multiple neuropeptides stimulate clonal growth of small cell lung cancer: Effects of bradykinin, vasopressin, cholecystokinin, galanin, and neurotensin. Cancer Research 51:3621-3623.
49. Shepherd FA, Giaccone G, Seymour L, Debruyne C, Bezjak A, Hirsh V, Smylie M, Rubin S, Martins H, Lamont A, Krzakowski M, Sadura A, Zee B. 2002. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. Journal of Clinical Oncology 20:4434-4439.
50. Sherr CJ, Roberts JM. 1999. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes and Development 13:1501-1512.
51. Sixt M, Bauer M, Lammermann T, Fassler R. 2006. Beta1 integrins: Zip codes and signaling relay for blood cells. Current Opinions in Cell Biology 18:482-490.
52. Smith PJ, Soues S, Gottlieb T, Falk SJ, Watson JV, Osborne RJ, Bleehen NM. 1994. Etoposide-induced cell cycle delay and arrest-dependent modulation of DNA topoisomerase II in small-cell lung cancer cells. British Journal of Cancer 70:914-921.
53. Smith PJ, Wiltshire M, Chin SF, Rabbitts P, Soues S. 1999. Cell cycle checkpoint evasion and protracted cell cycle arrest in X-irradiated small-cell lung carcinoma cells. International Journal of Radiation Biology 75:1137-1147.
54. Su JM, Gui L, Zhou YP, Zha XL. 2002. Expression of focal adhesion kinase and alpha5 and beta1 integrins in carcinomas and its clinical significance. World Journal of Gastroenterology 8:613-618.
55. Tian B, Lessan K, Kahm J, Kleidon J, Henke C. 2002. Beta 1 integrin regulates fibroblast viability during collagen matrix contraction through a phosphatidylinositol 3-kinase/Akt/protein kinase B signaling pathway. Journal of Biological Chemistry 277:24667-24675.
56. Tong W, Pollard JW. 2001. Genetic evidence for the interactions of cyclin D1 and p27(Kip1) in mice. Molecular and Cellular Biology 21:1319-1328.
57. Uhm JH, Dooley NP, Kyritsis AP, Rao JS, Gladson CL. 1999. Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death. Clinical Cancer Research 5:1587-1594.
58. Vidal A, Koff A. 2000. Cell-cycle inhibitors: three families united by a common cause. Gene 247:1-15.
59. Woo RA, Poon RY. 2003. Cyclin-dependent kinases and S phase control in mammalian cells. Cell Cycle 2:316-324.
60. Wu AH, Henderson BE, Thomas DC, Mack TM. 1986. Secular trends in histologic types of lung cancer. Journal of the National Cancer Institute 77:53-56.
61. Ylisirnio S, Hoyhtya M, Turpeenniemi-Hujanen T. 2000. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer-TIMP-1 as a prognostic marker. Anticancer Research 20:1311-1316.